FDA approved nanomedicines Nanomedicine Biology Material Chemistry - PowerPoint PPT Presentation

FDA approved nanomedicines Nanomedicine Biology Material Chemistry Imaging Drugs Smart 100~300 nm agents delivery Molecules, 2017 Daniel Bobo, Pharmacutical research, 2016

“Korea Drug Development Fund” 0.9 million dollars (~ 2019.8) (1 billion US dollars fund by Korea ministries) for scale-up and formulation

A simple tumor-specific and self-assembly peptide-drug conjugate Higher mag. Doxorubicin Hydrophobic Hydrophilic peptide Peptide 120 HT-29 cancer cell 100 Cell viability (%) 80 HT-29 tumor cell H9C2 normal cell 60 40 Free DOX DOX DOX FRRG-DOX 20 FRRG-DOX FRRG-DOX 0 0.01 0.1 1 10 100 1000 Concentration (uM) 120 H9C2 normal cell Cell viability (%) 100 80 60 40 Free DOX 20 24 h 24 h FRRG-DOX 0 0.01 0.1 1 10 100 1000 Concentration (uM) (Unpublished data)

Anticancer effect in HT29- tumor bearing mice Cardiac toxicity indicators in blood ( rats) 3000 Tumor volume ( mm3 ) 3 Saline ** 10 hs troponin - T ** Troponin-I 2500 DOX 2 FRRG-DOX 5 2000 1 1500 0 0 Saline FRRG-DOX DOX Saline FRRG-DOX DOX 1000 500 ** 1500 ** CK-MM (U/L) 1000 CPK total (S) 0 0 2 4 6 8 10 12 14 16 1000 500 Time (day) 500 0 26 0 Saline FRRG-DOX DOX Saline FRRG-DOX DOX Mouse weight (g) 24 Electrocardiography (ECG) in mice after treatment 22 QTc-B(ms) QTc-V(ms) Control 0.5 mV 106.4 ± 2.2 20 81.6 ± 5.0 0.2 s Saline 18 DOX DOX 100.9 ± 9.8 114.9 ± 4.6 FRRG-DOX 16 0 2 4 6 8 10 12 14 16 FRRG 77.8 ± 3.12 105.5 ± 1.25 Time (day) -DOX (Unpublished data)